Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Yoshinori, Tanizawa"'
Autor:
Etsuko Awaki, Takao Takeshima, Yasuhiko Matsumori, Koichi Hirata, Naoki Miyazaki, Ryo Takemura, Satoshi Osaga, Yoshinori Tanizawa, Mika Komori
Publikováno v:
Neurology and Therapy, Vol 13, Iss 1, Pp 165-182 (2024)
Abstract Introduction The impacts of migraine on daily life, including daily activities and fundamental health indicators (sleep and mental health), have not been described in detail for people with migraine in Japan. Methods The cross-sectional Obse
Externí odkaz:
https://doaj.org/article/12785cdb740641219cb921d5469aa267
Autor:
Chie Masaki, Kiminori Sugino, Yoshinori Tanizawa, Kenichi Nakamura, Yui Okada, Zhihong Cai, Takahiro Okamoto
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 1, Pp 145-158 (2022)
Abstract Background The multikinase inhibitors (MKIs) sorafenib, lenvatinib, and vandetanib are approved for advanced thyroid cancer (TC) in Japan. How sequential treatment with MKIs is conducted in Japanese clinical practice is unknown. Methods This
Externí odkaz:
https://doaj.org/article/ba28694c67674e1fae1bf5a8bdebaaf9
Autor:
Eiji Shinozaki, Akitaka Makiyama, Yoshinori Kagawa, Hironaga Satake, Yoshinori Tanizawa, Zhihong Cai, Yongzhe Piao
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0246160 (2021)
The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the facto
Externí odkaz:
https://doaj.org/article/8a6b6f8616b04dc1a6995cdd76416fb3
Publikováno v:
Advances in Therapy. 39:4792-4807
Treatment options in patients with mantle cell lymphoma (MCL) failing ibrutinib are limited, with no standard therapies defined. This study aimed to investigate real-world treatment patterns and outcomes for patients with MCL following ibrutinib.This
Autor:
Dai Maruyama, Chaochen Wang, Yoshinori Tanizawa, Zhihong Cai, Yujing Huang, Masaomi Tajimi, Shigeru Kusumoto
Publikováno v:
Journal of Clinical & Experimental Hematopathology; 2023, Vol. 63 Issue 4, p219-229, 11p
Autor:
Hironaga Satake, Yoshinori Kagawa, Eiji Shinozaki, Yoshinori Tanizawa, Long Jin, Zhihong Cai, Akitaka Makiyama
Publikováno v:
Advances in Therapy. 39:2596-2613
Evidence is lacking on second-line and later treatments for patients with RAS wild-type colorectal cancer (CRC) who receive first-line anti-epidermal growth factor receptor (EGFR) antibody therapy. In this study, we explored the real-world treatment
Autor:
Shuichi Hironaka, Yoshinori Tanizawa, Yoshito Komatsu, Narikazu Boku, Yongzhe Piao, Zhihong Cai
Publikováno v:
Advances in Therapy
Introduction Clinical trials have proven the efficacy and safety of new therapies for advanced gastric cancer (AGC), but how those therapies are used in the real world is poorly described. Real-world treatment patterns of antitumor therapies and fact
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 49(12)
This study aims to evaluate Japanese patients' preferences in first-line therapy choice for advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)mutations.A cross-sectional discrete-choice experiment was conducted on a
Autor:
Jan-Stefan van der Walt, Joji Mori, Takahiro Nakayama, Kenichi Inoue, Yoshinori Ito, George W. Sledge, Yasuo Miyoshi, Tsutomu Kawaguchi, Masato Takahashi, Yoshinori Tanizawa, Masakazu Toi, Antonio Llombart-Cussac, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai, Sachi Sakaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-neg
Autor:
Masaaki Kawai, Masahiro Takada, Takahiro Nakayama, Norikazu Masuda, Hirokazu Shiheido, Zhihong Cai, Yu-Jing Huang, Tsutomu Kawaguchi, Yoshinori Tanizawa
Publikováno v:
Breast cancer research and treatment. 197(2)
Purpose The aim was to understand real-world cyclin-dependent kinase (CDK) 4 and 6 inhibitor use in Japan. Methods This retrospective observational study used a Japanese administrative claims database and included patients with presumptive hormone re